Long-term persistence of TCR-T cells, in the absence of supplemental IL-2, was seen in the patient with MDS, supporting the contention that greater clinical benefit may be achieved in patients with lower disease burdens. This evidence concerns the gene IL2 and myelodysplastic syndrome.